Emmaus CEO buys 530K shares in open market
Emmaus Life Sciences’ CEO reported indirect open‑market purchases totaling 530,767 EMMA shares across 2025–2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Emmaus Life Sciences, Inc. (EMMA) discloses that CEO and director Willis C. Lee, through retirement accounts, reported a series of open-market purchases of common stock. Between May 30, 2025 and August 31, 2026, entities for his benefit bought an aggregate 530,767 shares at weighted average prices generally ranging from about $0.01 to $0.075 per share, all reported as indirect ownership.
Insider Trade Summary
Net Buyer: 530,767 shares
Net Buy
8 txns
Insider
LEE WILLIS C
Role
CEO
Bought
530,767 shs ($18K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common stock, $0.001 par value F6 | 100,000 | $0.05 | $5K |
| Purchase | Common stock, $0.001 par value F5 | 94,767 | $0.06 | $6K |
| Purchase | Common stock, $0.001 par value F4 | 50,000 | $0.05 | $3K |
| Purchase | Common stock, $0.001 par value F3 | 46,000 | $0.04 | $2K |
| Purchase | Common stock, $0.001 par value F2 | 170,000 | $0.01 | $2K |
| Purchase | Common stock, $0.001 par value F1 | 70,000 | $0.02 | $1K |
| holding | Common stock, $0.001 par value | -- | -- | -- |
| holding | Common stock, $0.001 par value | -- | -- | -- |
Holdings After Transaction:
Common stock, $0.001 par value — 690,167 shares (Indirect, Fidelity Roth IRA FBO Willis C. Lee);
Common stock, $0.001 par value — 395,124 shares (Direct);
Common stock, $0.001 par value — 241,194 shares (Indirect, Fidelity Traditional IRA FBO Willis C. Leeee)
Footnotes (6)
- F1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.01 to $0.02, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1), footnote (2), footnote (3), footnote (4), footnote (5) and footnote (6).
- F2. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.0109 to $0.011, inclusive.
- F3. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.034 to $0.039, inclusive.
- F4. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.044 to $0.051, inclusive.
- F5. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.050 to $0.075, inclusive.
- F6. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.046 to $0.05, inclusive.
Key Figures
Total shares purchased: 530,767 shares
Latest purchase size: 100,000 shares
Latest weighted average purchase price: $0.05 per share
+4 more
7 metrics
Total shares purchased
530,767 shares
Aggregate open-market purchases reported across six transactions from May 30, 2025 to August 31, 2026
Latest purchase size
100,000 shares
Shares bought on August 31, 2026 in an indirect account
Latest weighted average purchase price
$0.05 per share
Weighted average price for the August 31, 2026 100,000‑share purchase (range $0.046–$0.05)
Price range for May 30, 2025 purchase
$0.01–$0.02 per share
Range of individual trade prices for the 70,000‑share purchase on May 30, 2025
Price range for August 28, 2026 purchase
$0.050–$0.075 per share
Range of individual trade prices for the 94,767‑share purchase on August 28, 2026
Direct holdings
395,124 shares
Common stock held directly as of May 30, 2025 holding entry
Indirect traditional IRA holdings
241,194 shares
Common stock held indirectly through a traditional IRA as of May 30, 2025 holding entry
Key Terms
weighted average price, indirect ownership, open market or private transaction
3 terms
weighted average price financial
"The price reported is a weighted average price. These shares were purchased"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirect ownership financial
"reported as indirect ownership through retirement accounts for the benefit of Willis"
open market or private transaction financial
"Purchase in open market or private transaction"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider trading activity did EMMA report for CEO Willis C. Lee?
The report shows that entities for the benefit of CEO Willis C. Lee purchased 530,767 shares of Emmaus Life Sciences common stock in open‑market transactions between May 30, 2025 and August 31, 2026, all reported as indirect ownership.
Were the EMMA insider purchases made under a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5‑1 checkbox is not marked as affirmative, and the footnotes describe weighted average open‑market purchases but do not state that they were made under a Rule 10b5‑1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
